Modulation of erythrocyte deformability by PKC activity

Area of Science:

• Red blood cell biology
• Cellular signaling
• Biochemistry

Background:

• Erythrocyte deformability (EEI) is crucial for blood flow, maintained by interactions between membrane, peripheral, and cytoskeleton proteins.
• Protein band 3 phosphorylation by phosphotyrosine kinases (PTK) and phosphotyrosine phosphatase (PTP) is a key regulatory process.
• A previously identified pathway links erythrocyte membrane protein acetylcholinesterase (AChE) to protein band 3.

Purpose of the Study:

• To investigate how protein kinase C (PKC) activity modulates erythrocyte deformability (EEI) under varying conditions of band 3 phosphorylation and AChE effector presence.
• To elucidate the interplay between PKC, band 3 phosphorylation, and AChE signaling in regulating red blood cell mechanics.

Main Methods:

• Utilized phorbol 12-myristate 13-acetate (PMA) to activate PKC and chelerythrine chloride to inhibit PKC.
• Employed band 3 modulators to alter band 3 phosphorylation degrees.
• Measured EEI in whole blood samples in the presence and absence of AChE effectors (velnacrine, ACh).
• Used calpeptin to assess its impact on EEI under different PKC and band 3 phosphorylation conditions.

Main Results:

• PKC inhibition significantly decreased EEI, both with and without the AChE inhibitor velnacrine.
• PMA treatment increased EEI, irrespective of the presence or absence of ACh.
• Calpeptin decreased EEI, even when combined with chelerythrine or PMA.

Conclusions:

• Erythrocyte deformability is directly dependent on cytoskeleton proteins, PKC activity, and band 3 phosphorylation levels.
• Understanding these protein interactions and signal transduction mechanisms may reveal potential drug targets for modulating EEI.